Xiong Lab, Lineberger Comprehensive Cancer Center,University of North Carolina at Chapel Hill


 
 
 
 


 

Research articles

1.  Li, Y., Jenkins, C., Nichols, M., and Xiong, Y. (1994).  Cell Cycle Expression and p53 Regulation of the Cyclin-Dependent Kinase Inhibitorp21.  Oncogene 9:2261-2268.

2.  Li, Y., Nichols, M. A., Shay, J. W. and Xiong, Y. (1994). Transcriptional repression of the cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product, pRb.  Cancer Research  54:6078-6082.

3.  Guan, K-L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X.,O'Keefe, C. L., Matera, G. and Xiong, Y.  (1994).   Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes& Development 8:2939-2952.   Read Abstract

4. Yee, A., Nichols, M. A., Wu, L., Hall, F. L., Kobayashi, R. and Xiong, Y. (1995).  Molecular cloning of CDK7-associated human MAT1, a CDK-activating kinase (CAK) assembly factor.  Cancer Research  55:6058-6062

5.  Guan, K-L., Jenkins, C., Li, Y., Christine L. O'Keefe, Zariwala,M., Noh, S., Wu, X., Matera, A. G. and Xiong, Y. (1996)  Isolation and Characterization of p19INK4d,a p16-related inhibitor specific to CDK6 and CDK4.   Molecular Biology of the Cell 7:57-70. Read Abstract

6.  Zariwala, M., Liu, E. and Xiong, Y. (1996).  Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15MTS2/INK4b and p18 in tumor-derived cell lines and primary tumors. Oncogene 12:451-455.

7.  Xiong, Y., Kuppuswamy, D., Li, Y., Livanos, E.M., Hixon, M., White,A., Beach, D. and Tlsty, T. D. (1996).  Alteration of cell cycle kinase complexes in human papilloma virus E6- and E7-expressing fibroblasts precedes neoplastic transformation.  Journal of Virology 70:999-1008.Read Abstract

8.  Franklin, D. F. and Xiong, Y. (1996).  Induction of CDK inhibitor p18 and its predominant association with CDK4 and CDK6 during myogenic differentiation.   Mol. Biol. Cell  7:1587-1599.   Read Abstract

9.  Zariwala, M. and Xiong, Y. (1996).  Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors.   Oncogene  13:2033-2038.

10. Phelps, D., Hsiao, K-M., Li, Y., Hu, N., Franklin, D. S., Westphal, E.,Lee, E.,  and Xiong, Y. (1998). Coupled transcriptional and translational control of CDK inhibitor p18INK4cs expression during myogenesis. Molecular and Cellular Biology 18:2334-2343. Read Article

11. Watanabe, H., Pan, Z-Q., Schreiber-Agus, N., DePinho, R. A., Hurwitz, J. and Xiong, Y. (1998).  Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. USA 95:1392-1397. Read Article

12. Zhang, Y., Xiong, Y., and Yarbrough, W. G. (1998).  ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.  Cell 92:725-734. Read Article

13. Michel, J., and Xiong, Y. (1998) Human cullin 1, but not other cullin family members, selectively interacts with SKP1 to form a complex withSKP2 and cyclin A.  Cell Growth Differentiation 9:439-445. Read Abstract

14. Phelps, D. E., and Xiong, Y. (1998).  Regulation of CDK4during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1. Cell Growth Differentiation. 9:595-610.   Read Abstract

15. Franklin D. S., Godfrey, V. L., Lee, H., Kovalev, G. I., Schoonhoven,R., Chen-Kiang, S., Su, L., Xiong, Y. (1998). CDK inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes & Development 12:2899-2911. Read Article

16. Zariwala, M. Liu, J., and Xiong, Y.  (1998).  Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins.  Oncogene17:2787-2798.  Read Article

17. Ohta, T,  Michel, J. J., Schottelius, A. J.,  and Xiong, Y. (1999).   ROC1, a homologue of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Molecular Cell3:535-541.   Read Article

18. Zhang, Y., and Xiong, Y. (1999).  Tumor derived mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.  Molecular Cell 3:579-591. Read Article

19. Ohta, T,  Michel, J, and Xiong, Y.  (1999).  Association with cullin partners protects ROC proteins from proteasome-dependent degradation. Oncogene 18:6756-6766.   Read Article

20. Franklin, DS, Godfrey, VL, O’Brien, DA, Deng, C, and Xiong, Y. (2000).  Functional collaboration between different CDK inhibitors suppress tumor growth with distinct tissue specificity.  Molecular and Cellular Biology 20:6147-58. Read Article

21. Furukawa, M, Zhang, Y, McCarville, J, Ohta, T, and Xiong, Y. (2000).  The CUL1 C-terminal sequence and ROC1 promote nuclear accumulation and NEDD8 modification of CUL1, resulting in efficient ubiquitin ligase activity. Molecular and Cellular Biology 20:8185-8197.  Read Article

22. Ohta, T, and Xiong, Y.  (2001).  Phosphorylation- andSKP1-independent in vitro ubiquitination of E2F1 by multiple ROC-cullin ligases. Cancer Research 61:1347-1353.   Read Article

23. Zhang, Y, and Xiong, Y. (2001).  A role of p53 N-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation.  Science 292:1910-1915.   Read Article

24. Furukawa, M, Ohta, T, Xiong, Y. (2002). Activation of UBC5 ubiquitin conjugating (E2) enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins. Journal of Biological Chemistry 277:15758-15765.  Read Article

25. Yarbrough, WG, Bessho, M, Zanation, A, Bisi, JE, Xiong, Y. (2002). Human tumor suppressor ARF impedes S-phase progression independent of p53. Cancer Research 62:1171-1177.  Read Article

26. Liu, J, Furukawa, M, Matsumoto,T, Xiong, Y, (2002). NEDD8 modification ofCUL1 dissociates p120CAND1, an inhibitor of CUL1-SKP1 binding and SCF ligases. Molecular Cell 10:1511-1518. Read Article

27. Bai, F, Pei, XH, Godfrey, VL, Xiong, Y. (2003). Haploinsufficiency of p18INK4csensitizes mice to carcinogen-induced tumorigenesis. Molecular and Cellular Biology 23:1269-1277. Read Article

28. Shumway, SD, Li Y, Xiong, Y. (2003). 14-3-3bbinds to and negatively regulates the tuberous sclerosis complex 2 (TSC2) tumor suppressor gene product, tuberin. Journal of Biological Chemistry 278:2089-2092. Read Article

29. Michel, JJ, McCarville, J, Xiong, Y. (2003). A role for Saccharomyces cerevisiae CUL7 ubiquitin ligase in proper anaphase progression.  Journal of Biological Chemistry 278:22828-22837. Read Article

30.  Furukawa, M, He, YJ, Borchers, C, Xiong, Y. (2003). Targeting protein ubiquitination by BTB-cullin 3-Roc1 ubiquitin ligases.  Nature Cell Biology  5:1001-1007. Read Article

31.  Zhang, Y, Whitewolf, G, Allio, T, Jin, A, Bhat, K, Burkhart, W, Xiong, Y. (2003). Ribosomal protein L11 binds to and negatively regulates oncoproteins HDM2.  Molecular and Cellular Biology 23:8902-8912. Read Article

32.  Feng, S, Shen Y, Sullivan, JA, Rubio, V, Xiong, Y, Sun, TP, Deng, XW. (2004) The Arabidopsis thaliana CAND1, an unmodified CUL1 interacting protein, is involved in multiple development pathways controlled by ubiquitin/proteasome-mediated protein degradation.  Plant Cell 16:1870-1882. Read Article

 

33.  Pei, XH, Bai, F, Tsutsui, T, Kiyokawa, H, Xiong, Y. (2004) Genetic evidence for functional dependency of p18Ink4c on CDK4.  Mol Cell Biol 24:6653-6664.  Read Article

 

34.  Goldenberg, SL, Cascio, TC, Shumway, SD, Garbutt, KC, Liu, J, Xiong, Y, Zheng, N. (2004) Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multi-subunit cullin-based ubiquitin ligases.  Cell in press 

 

35.  Hu, J, McCall, CM, Ohta, T, Xiong, Y.  (2004) Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol in press

 

36.  Furukawa, M, Xiong, Y.  (2004) The BTB protein Keap1 targets the antioxidant transcription factor Nrf2 for ubiquitination by the cullin 3-Roc1 ligase. Mol Cell Biol in press

 

 

Reviews and book chapters

1.  Jenkins, C. W. and Xiong, Y.  (1995). Immunoprecipitation and immunoblotting in cell cycle studies. In Cell Cycle: Material and methods, M.Pagono ed. (New York: Springer-Verlag), pp. 250-263.

2. Xiong, Y. (1996).  Why are there so many CDK inhibitors ? Biochimica et Biophysica Acta 1288:1-5

3. Li, Y., Jenkins, C. W.,  Nichols, M. A.,Wu, X., Guan, K-L., and Xiong, Y. (1996).  p16 family inhibitors of cyclin-dependent kinase. Pezcoller Foundation Journal.  7:57-82.

4.  Phelps, D. and Xiong, Y. (1996).  Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6.  Method inEnzymology, W. Dunphy ed. 283:194-205.

5.  Zhang, Y. and Xiong, Y. (2001).  Control of p53 ubiquitination and nuclear export by MDM2 and ARF.  Cell Growth & Differentiation 12:175-186. Read Article